Special Considerations and Clinical Management of HIV in Patients With Substance Use Disorder
Summary
- Methadone levels may decrease when coadministered with the capsule formulation of lopinavir/ritonavir, with potential for clinical opioid withdrawal[Clarke 2002; McCance-Katz 2003]
- Interactions between buprenorphine and the tablet formulation of once-daily lopinavir/ritonavir are not clinically significant[Bruce 2010]
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content